Previous 10 | Next 10 |
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate Completed end-of-Phase II meeting with the FDA for IFX-1 in hidradeniti...
BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt BioNTech SE ( BNTX ) reported positive early data for its COVID-19 vaccine candidate, BNT162b1. The company is collaborating with Pfizer ( PFE ) for developing this vaccine candidate. BNT1...
InflaRx (NASDAQ: IFRX ) jumps 28% premarket on the heels of continued development of IFX-1 in severe COVID-19 induced pneumonia by initiating a Phase III trial, subject to regulatory approval. More news on: InflaRx N.V., Healthcare stocks news, Stocks on the move, Read ...
Immuron (NASDAQ: IMRN ) +114% on potential of hyperimmune bovine antibodies in COVID-19. More news on: Immuron Limited, Midatech Pharma plc, New Age Beverages Corporation, , , Stocks on the move Read more ...
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the...
Gainers: Cohen & Company (NYSEMKT: COHN ) +128% . More news on: Cohen & Company Inc., LM Funding America, Inc., Integrated Media Technology Limited, Stocks on the move, , Read more ...
Chembio Diagnostics (NASDAQ: CEMI ) -60% after FDA yanks emergency use authorization of COVID-19 blood test. More news on: Chembio Diagnostics, Inc., BioCardia, Inc., Beasley Broadcast Group, Inc., Stocks on the move, , Read more ...
InflaRx (NASDAQ: IFRX ) slumps 9% premarket on average volume in reaction to preliminary data from the first 30 subjects in a Phase 2/3 clinical trial evaluating IFX-1 plus best supportive care for up to 28 days in hospitalized patients with severe COVID-19 pneumonia. More ne...
IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe COVID-19 pneumonia InflaRx is now evaluating the continuation into a pla...
InflaRx (NASDAQ: IFRX ): Q1 GAAP EPS of -€0.32 beats by €0.20 . Cash, cash equivalents and financial assets of approximately €108M. Shares +1.4% . Press Release More news on: InflaRx N.V., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...